Percutaneous Renal Tumor Cryoablation Followed by Biopsy

Status Completed

Clinical Trial Summary

This study is being done to test how effective cryoablation is in killing cancer cells. Cryoablation uses freezing temperatures to treat cancer. Cryoablation works by creating freezing temperatures within a needle probe. When this probe is inserted into a cancer, the freezing temperatures are used to try and kill the cancer. Unfortunately, the investigators don't know how well cryoablation works at destroying the cancer. This study will allow us to check to see how well cryoablation works for kidney cancers. After the investigators destroy the kidney cancers using cryoablation, the investigators will followup with you every 5-7 months to make sure the cryoablation worked and that the cancer was destroyed.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01012427
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	Phase 1
Start date	November 2009
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03634540` - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)	Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT00531284` - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05842044` - NSAID Use After Robotic Partial Nephrectomy	Phase 2
Recruiting	`NCT05387863` - Decision Aid (DA) for Renal Patients	N/A
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Completed	`NCT04933604` - LPN in Patients With High-complex Renal Tumors
Withdrawn	`NCT03390413` - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer	N/A
Recruiting	`NCT05119335` - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT03203473` - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)	Phase 2
Suspended	`NCT04115254` - Stereotactic Magnetic Resonance Guided Radiation Therapy	N/A
Enrolling by invitation	`NCT02609269` - Decipher Genomics Resource for Intelligent Discovery
Completed	`NCT01444456` - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia	N/A
Terminated	`NCT01453595` - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)	Phase 1/Phase 2
Completed	`NCT02811250` - Stereotactic Radiotherapy for Renal Cancers	N/A
Completed	`NCT00398814` - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers	Phase 1
Completed	`NCT00399152` - Perifosine + Sunitinib Malate for Patients With Advanced Cancers	Phase 1
Completed	`NCT00458536` - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF	Phase 1/Phase 2
Recruiting	`NCT03693014` - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors	Phase 2
Completed	`NCT00418496` - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma	Phase 1